Nerio Therapeutics
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
Nerio Therapeutics, a San Diego-area drug discovery and development company, focused on phosphatases as therapeutic targets for cancer immunotherapy. It developed novel, potent and selective small-molecule inhibitors of protein tyrosine phosphatases PTPN1 and PTPN2, immune checkpoints whose blockade can boost immune cells to fight tumors. On July 29, 2024, Boehringer Ingelheim announced the acquisition of Nerio for a total of up to $1.3 billion.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Acquisition
Boehringer Ingelheim announces on July 29, 2024 that it is acquiring Nerio Therapeutics for up to $1.3 billion to anchor its immuno-oncology pipeline.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.